Figure 3
Only antigen-experienced anti-HA effector T cells are capable of eradicating HA tumors in the presence of Tregs. (a, b) Six-week-old BALB/c mice were injected i.v. with PBS (n=4, black line) or graded quantities of naive CD25− CD44low TCR-HA T cells from CMH-II restricted SFE transgenic mice: 1 × 106 (n=7, light gray line), 3 × 106 (n=8, gray line) or 9 × 106 (n=6, dark gray line) cells at day −1 and 5 × 105 AB1-HA (s.c.) at day 0. Graphs show (panel a), the Kaplan–Meyer survival curves and (panel b), the tumor volume growth curves (mm3). The treated groups were statistically different from the PBS-treated group (***P=0.0005, ***P=0.0002, ***P=0.0001, respectively, with a log-rank (Mantel–Cox) test). (c, d) TCR-HA transgenic mice were immunized in vivo s.c. with HA peptide in IFA. Two months later, mice were killed and the spleen and inguinal/political lymph nodes were harvested. Six-week-old BALB/c mice were injected s.c. with 5 × 105 AB1-HA at day 0 and i.v. with 15 × 106 effector T cells from immunized TCR-HA mice (n=5, gray line), containing ∼3 × 106 memory TCR-HA Teffs, or PBS (n=5, black line) at day 0. Graphs show (panel c), the Kaplan–Meyer survival curves and (panel d), the tumor volume growth curves (mm3). The treated group was statistically different from the PBS-treated group (*P=0.0157, with a log-rank (Mantel–Cox) test.
